Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer

Current oncology

R. Juergens¹  D.G. Bebb²  S. Banerji³  D.N. Ionescu⁴  P. Cheema⁵  C. Butts⁶  R. Albadine⁷  J. Agulnik⁸  S.A. Laurie⁹  M.S. Tsao^1,10  V. Hirsh^1,10  G. Liu^1,10  Z. Xu^1,11  N. Blais^1,11  J. Deschenes^1,13  V. Cohen^1,14  P. Cheung^1,15  W. Morzycki^1,16  D. Bethune^1,17  B. Melosky^1,18  S. Kamel-Reid^1,18 

[1] University of Alberta;University of Manitoba;CancerCare Manitoba;Cross Cancer Institute;Cross Cancer Institute, University of Alberta;Hôpital Notre-Dame;Hôpital St-Luc;Jewish General Hospital, McGill University;Juravinski Cancer Centre;Princess Margaret Cancer Centre, University Health Network;QEII Health Sciences Centre;Royal Victoria Hospital;Segal Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital;Sunnybrook Odette Cancer Center;Sunnybrook Odette Cancer Centre;The Ottawa Hospital Cancer Centre;Tom Baker Cancer Centre;Vancouver Centre, BC Cancer Agency

关键词: ALK;    anaplastic lymphoma kinase;    non-small-cell lung cancer;    molecular testing;    targeted inhibition;   

DOI  :  10.3747/co.23.3120

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Anaplastic lymphoma kinase (ALK) is an oncogenic driver in non-small-cell lung cancer (NSCLC). Chromosomal rearrangements involving theALKgene occur in up to 4% of nonsquamous NSCLC patients and lead to constitutive activation of the ALK signalling pathway.ALK- positive NSCLC is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis.Targeted inhibition of the ALK pathway prolongs progression-free survival in patients withALK- positive advanced NSCLC. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population.Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of anALKrearrangement. If anALKrearrangement is present, treatment with a targeted ALK inhibitor in the first-line setting is recommended. As patients become resistant to first-generation ALK inhibitors, other treatments, including second-generation ALK inhibitors can be considered.

【 授权许可】

Unknown